Main Article Content
Introduction: The etiology of COVID-19 is related to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) virus, which gains entry into host cells through the utilization of angiotensin converting enzyme-2 (ACE 2) receptors located on the cellular membrane. The user's text is already academic. Numerous investigations have documented the range of clinical presentations associated with the condition and emphasized the impact on the cardiovascular system.
Methods: We conducted a literature search of PubMed, Medline, EMBASE, and Google Scholar databases identified all relevant studies reporting cardiovascular comorbidities, disease severity, and survival. It was conducted to assess the demographic characteristics and prevalence of hypertension and congestive heart failure among individuals diagnosed with COVID-19 and to evaluate the death rates in patients with COVID-19 infection who also have hypertension and congestive heart failure.
Results: The study encompassed a diverse spectrum of patients, spanning from 23 to 95 years of age. The prevalence of females within the sample varied between 19% and 52%. The study findings revealed that the incidence rates of hypertension, diabetes mellitus, and smoking varied between 10% and 82%, 8% and 24%, and 4% and 14%, respectively. Our study revealed a statistically significant increase in the risk of death among patients with congestive heart failure, with a relative risk of 3.38 (1.80-6.32) and a p-value of 0.004.
Conclusion: In brief, the coexistence of congestive heart failure (CHF) in individuals diagnosed with COVID 19 is linked to heightened death rates and unfavorable outcomes throughout the initial hospitalization period.
2. Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations ofCOVID-19. Circulation. 2020; 141:1930e1936.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. J Am Med Assoc. 2020.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497e506.
5. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133:1025e1031.
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507e513.
7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708e1720.
8. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Curr Probl Cardiol. 2020;45:100617.
9. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xinxueguanbing Zazhi. 2020;48:E004.
10. Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020.
11. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. J Am Med Assoc. 2020.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6, e1000097.
13. IoMUCotSaEIoDi Biomedicine. Society’s Choices: Social and Ethical Decision Making in Biomedicine. Washington (DC): National Academic Press (US); 1995.
14. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020.
15. Rothman K, Greenland S, Lash T. Modern Epidemiology. 2008.
16. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Stratification for confounding–part 1: the Mantel-Haenszel formula. Nephron Clin Pract. 2010;116:317-321.
17. Inthout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
18. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
19. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Base Ment Health. 2019;22:153-160.
20. W V. Conducting meta-analyses in R with the metafor package. J Stat Software. 2010;36:1-48.
21. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
22. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92:797-806.
23. Hu L, Chen S, Fu Y, et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in wuhan, China. Clin Infect Dis. 2020.
24. Yang Q, Xie L, Zhang W, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Therapeut. 2020;45:609-616.
25. Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116e-121.
26. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
27. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12:11245-11258.
28. Lu H, Ai J, Shen Y, et al. A Descriptive Study of the Impact of Diseases Control and Prevention on the Epidemics Dynamics and Clinical Features of SARS-CoV-2 Outbreak in Shanghai, Lessons Learned for Metropolis Epidemics Prevention. 2020.
29. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531-538.
30. Shamshirian A, Heydari K, Alizadeh-Navaei R, Moosazadeh M, Abrotan S, Hessami A. Cardiovascular Diseases and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-Analysis. 2020.
31. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020.
32. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-637.
33. South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic: the pediatric perspective. Hypertension. 2020;76:16-22.
34. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097-1100.
35. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618-625.
36. South AM, Shaltout HA, Washburn LK, Hendricks AS, Diz DI, Chappell MC. Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data. Clin Sci (Lond). 2019;133:55-74.
37. Rali AS, Ranka S, Shah Z, Sauer AJ. Mechanisms of myocardial injury in coronavirus disease 2019. Card Fail Rev. 2020;6:e15.
38. Kochav SM, Coromilas E, Nalbandian A, et al. Cardiac arrhythmias in COVID-19 infection. Circ Arrhythm Electrophysiol. 2020;13, e008719.
39. Dridi H, Kushnir A, Zalk R, Yuan Q, Melville Z, Marks AR. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Rev Cardiol. 2020.
40. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-260.
41. Januzzi Jr JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
42. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation. 2005;112:527-534.
43. Pirracchio R, Deye N, Lukaszewicz AC, et al. Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med. 2008;36:2542-2546.
44. Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21:83.
45. Pranata R, Huang I, Lukito AA, Raharjo SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med. 2020;96: 387-391.